GENERICS, the bane of the research-based pharmaceutical industry, are a very important aspect of the health care industry to monitor, as more and more governments around the world are pushing for their greater use in order to contain health care budgets, while the launch of copy products on patent expiry - and often even before this actually occurs - can wipe billions of dollars off drugmakers’ revenues.